Fig. 6

OX40/OX40L blockade in vivo. a, b Treatment with anti-OX40L mAb on days 1–4 (a, n = 6) (IgG, n = 8) and days 14–17 (b, n = 4) (IgG, n = 6) after the second immunization ameliorated arthritis development in CIA mice. Arrows indicate the days of dosing. c Splenocytes from CIA mice treated with anti-OX40L mAb (n = 6) demonstrated reduced proliferation in CII stimulation compared with those treated with IgG (n = 6). d Cytokine secretion in the supernatants of splenocytes from CIA mice treated with anti-OX40L mAb (n = 6) or IgG controls (n = 6). e Cytokine production of CD4⁺CD28⁻OX40⁺ and the other control T-cell subsets after the splenocytes from CIA mice treated with anti-OX40L mAb (n = 5) or IgG controls (n = 5) were stimulated with PMA/ionomycin. Bars show mean ± SD; * P < 0.05, ** P < 0.01. CIA Collagen-induced arthritis, CII Collagen type II, IgG Immunoglobulin G, mAb Monoclonal antibody